Cufence

RSS

trientine dihydrochloride

Authorised
This medicine is authorised for use in the European Union.

Overview

Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition.
Cufence contains the active substance trientine dihydrochloride.

This EPAR was last updated on 17/06/2021

Authorisation details

Product details
Name
Cufence
Agency product number
EMEA/H/C/004111
Active substance
trientine dihydrochloride
International non-proprietary name (INN) or common name
trientine dihydrochloride
Therapeutic area (MeSH)
Hepatolenticular Degeneration
Anatomical therapeutic chemical (ATC) code
A16A
Publication details
Marketing-authorisation holder
Univar Solutions BV
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
25/07/2019
Contact address

Schouwburgplein 30-34
3012 CL Rotterdam
Netherlands

Product information

20/05/2021 Cufence - EMEA/H/C/004111 - II/0007/G

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating